The clinical pharmacology of methotrexate. new applications of an old drug

Cancer

Volumn 41, Issue 1, 1978, Pages 36-51

  Bleyer, W Archie ^a  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

CANCER CHEMOTHERAPY; DERMATOMUCOSAL AGENT; RHEUMATOLOGY;

ABSORPTION; BONE MARROW; CELL CYCLE; DRUG INTERACTIONS; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; HISTORY OF MEDICINE, 20TH CENT.; HUMAN; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; LEUCOVORIN; METHOTREXATE; NEOPLASMS; NERVOUS SYSTEM; RESEARCH DESIGN; SUPPORT, U.S. GOV'T, P.H.S.; TISSUE DISTRIBUTION; UNITED STATES;

EID: 0017873070     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I     Document Type: Article

References (151)

1. Acute Leukemia Group B: Acute lymphocytic leukemia in children. Maintenance therapy with methotrexate administered intermittently
2. A study of the distribution of methotrexate in human tissues and tumors
3. Leukoencephalopathy in children with acute lymphocytic leukemia receiving preventative central‐nervous‐system therapy
4. Methyltetrahydrofolic acid mediates N‐ and O‐methylation of biogenic amines
5. Immunologic suppression by methotrexate in dermatology
6. Alteration of methotrexate uptake in human leukemia cells by other agents
7. Induction of dihydrofolate reductase: Purification and properties of the “induced” human erythrocyte and leukocyte enzyme and normal bone marrow enzyme
8. Increased levels of dihydrofolic reductase in leucocytes of patients treated with amethopterin
9. Resistance to chemotherapeutic agents, clinical aspects
10. Computed tomographic appearance of methotrexate‐induced necrotizing leukoencepholopathy
11. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage schedule derived from age‐related pharmacokinetics
12. Methotrexate: Clinical‐pharmacology, current status and therapeutic guidelines
13. Pharmacokinetics and neurotoxicity of intrathecal methotrexate therapy
14. Concentration x time” methotrexate therapy of meningeal leukemia via a subcutaneous reservoir: A controlled clinical trial (abstr.)
15. Inhibition of renal tubular transport of methotrexate by probenicid
16. Leukoencephalopathy following combined irradiation and intraventricular methotrexate therapy of brain tumors in childhood
17. Interaction of chemotherapeutic agents with methotrexate and 5‐fluorouracil and its effect on de novo DNA synthesis
18. Long‐term remissions following one and two‐dose chemotherapy for African lymphoma
19. Improvement in the therapeutic index of methotrexate (NSC‐740) by L‐asparaginase (NSC‐109229)
20. Methotrexate therapy of Wegener's granulomatosis
21. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity
22. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues
23. Perspective on highdose methotrexate therapy
24. High‐dose methotrexate therapy in carcinoma of the pancreas
25. Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients
26. Site of action of methotrexate in psoriasis
27. Renal toxicity of methotrexate
28. Failure of leucovorin rescue to prevent reactivation of a solar burn after high‐dose methotrexate
29. Methotrexate in liver and bile after intravenous dosage in man
30. Pharmacokinetic considerations in resistance to anti‐cancer drugs
31. Methotrexate infusions and intensive supportive care in the management of children with acute‐lymphocytic leukemia: Follow‐up report
32. Methotrexate and citrovorum factor rescue in the management of childhood lympho‐sarcoma and reticulum cell sarcoma (non‐Hodgkin's lymphomas). Prolonged unmaintained remission
33. Massive dose citrovorum factor rescue and charcoal filtration following high‐dose methotrexate
34. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer
35. Irradiation, methotrexate toxicity, and the treatment of meningeal leukemia
36. High dose methotrexate therapy for disseminated malignant melanoma
37. Perturbation of generation cycle of human leukemic myeloblasts in vivo by methotrexate
38. Temporary remissions in acute leukemia in children produced by folic antagonist 4‐amethopteroylglutamic acid (aminopterin)
39. Intracerebral calcifications appearing during the course of acute lymphocytic leukemia treated with methotrexate and x‐rays
40. Methotrexate revisited
41. New approaches to cancer chemotherapy with methotrexate
42. Topical methotrexate in psoriasis
43. Leukoencephalopathy following chemotherapy for rhabdomyosarcoma: Reversibility of cerebral changes demonstrated by computed tomography
44. Paraplegia following intrathecal methotrexate. Report of a case and review of the literature
45. Adverse effects of intrathecal methotrexate in children with acute leukemia in remission
46. Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern
47. The characteristics of membrane transport of amethopterin and naturally‐occurring folate
48. The mechanism of action of methotrexate. I. Interaction with a low‐affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L‐cell mouse fibroblasts
49. The mechanism of action of methotrexate. II. Augmentation by vincristine of inhibition of deoxyribonucleic acid synthesis by methotrexate in Ehrlich ascites tumor cells
50. The variability of individual tolerance to methotrexate in cancer patients
51. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man
52. Parenchymatous degeneration of the central nervous system in childhood leukemia
53. Selective folinic acid (CF) protection” as opposed to “CF rescue” in L5178Y cells
54. Unbalanced deoxyribonucleotide synthesis caused by methotrexate
55. Thymidine rescue of methotrexate in man
56. Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical‐biochemical correlates
57. Pharmacokinetics of methotrexate
58. Effects of extracorporeal charcoal hemoperfusion on plasma methotrexate
59. High dose methotrexate therapy of solid tumors: Observations relating to clinical toxicity
60. Methotrexate and azothioprine treatment of childhood dermatomyositis
61. Altered plasma pharmacokinetics of methotrexate administered intrathecally
62. 1)) by human liver
63. A radioisotopic assay method for hepatic methotrexate oxidase activity in man and Rhesus monkey
64. Rescue from highdose methotrexate: Correlation between 30 hour methotrexate concentration and dose of leucovorin
65. Adjuvant methotrexate and citrovorum‐factor treatment of osteogenic sarcoma
66. Weekly high‐dose methotrexate‐citrovorum factor in osteogenic sarcoma
67. Toxicity of high‐dose methotrexate (NSC‐740) and citrovorum factor (NSC‐3590) in osteogenic sarcoma
68. Biochemical studies of methotrexate resistance in choriocarcinoma of human placenta and testis
69. Secretion of methotrexate into human milk
70. Chemotherapy of advanced squamous cell carcinoma of the anus with high‐dose methotrexate or continuous infusion bleomycin, vincristine and methotrexate
71. Encephalopathy in acute leukaemia associated with methotrexate therapy
72. Modes of uptake of methotrexate by normal and leukemic human leukocytes, in vitro and their relation to drug response
73. A clinical trial of high dose methotrexate with leucovorin “rescue” in advanced epidermoid carcinoma of the head and neck
74. Dose‐response of osteogenic sarcoma and lung carcinoma to methotrexate‐citrovorum
75. Response of childhood glioma to methotrexate‐citrovorum rescue
76. Induction of remission in acute leukemia of childhood by combination of prednisone and either 6‐mercaptopurine or methotrexate
77. Spontaneous remission or response to methotrexate in sarcoidosis
78. N‐methylation of dopamine to epinine in brain tissue using N‐methyltetrahydrofolic acid as the methyl donor
79. Vasculitis as a complication of high‐dose methotrexate in the treatment of acute leukemia
80. Kinetic model for the disposition and metabolism of moderate and high‐dose methotrexate (NSC‐740) in man
81. Improved therapeutic index of methotrexate with “leucovorin rescue”
82. The effect of organic acids on renal clearance of methotrexate in man
83. Renal toxicity of high‐dose methotrexate
84. Liver biopsy findings after methotrexate therapy for rheumatoid arthritis
85. The synergistic effect of salicylates on methotrexate toxicity
86. Cell kinetics and practical consequences for therapy of acute leukemia
87. Effect of lipid‐soluble esters of methotrexate on DNA synthesis in human skin
88. Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long‐term intermittent treatment
89. Methotrexate hepatotoxicity in children with leukemia
90. Effects of chemotherapy on the central nervous system. A study of parenteral methotrexate in long‐term survivors of leukemia and lymphoma in childhood
91. Polymyositis and dermatomyositis combined methotrexate and corticosteroid therapy
92. Immunosuppressive effects of cytosine arabinoside and methotrexate in man
93. Methotrexate meningitis
94. The pharmacokinetics of cyclophosphamide in man following treatment with methotrexate
95. Acute and chronic effects of methotrexate on hepatic, pulmonary and skeletal systems
96. High dose methotrexate therapy in carcinoma of the cervix
97. Serum methotrexate levels: the risk of clinical toxicity following high dose methotrexate with citrovorum factor rescue (abstr.)
98. Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors
99. Overview of protocols on clinical studies of high‐dose methotrexate (NSC‐740) with citrovorum factor (NSC‐3590) rescue
100. Abnormal computed tomography scans in children with acute lymphocytic leukemia following CNS prophylaxis
101. Weekly methotrexate citrovorum with alkalinization: Tumor response in a phase II study
102. Methotrexate‐citrovorum: Effect of alkalinization on nephrotoxicity and of weekly schedule on response
103. Clinical trial of high‐dose methotrexate (NSC‐740) with citrovorum factor (NSC‐3590)—toxicologic and therapeutic observations
104. Reversible dementia temporally associated with intraventricular therapy with methotrexate in a child with acute myelogenous leukemia
105. Liver injury associated with methotrexate therapy for psoriasis
106. A primate model for study of methotrexate pharmacokinetics in the central nervous system
107. Response, toxicity, and pharmacokinetics of high‐dose methotrexate (NSC‐740) with citrovorum factor (NSC‐3590) rescue for children with osteosarcoma and other malignant tumors
108. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy
109. Clinical pharmacokinetics—use of a mathematical model to guide high‐dose methotrexate infusion therapy
110. A pharmacokinetic model for high dose methotrexate with citrovorum factor rescue
111. Schedule dependence of cytosine arabinoside and methotrexate for recurrent childhood lymphocytic leukemia
112. Response of intracranial neoplasms to high‐dose methotrexate with citrovorum factor
113. Pontine glioma. High‐dose methotrexate and leucovorin rescue
114. Disseminated necrotizing leukoencephalopathy: A complication of treated central nervous system leukemia and lymphoma
115. The use of acetazolamide to alkalinize the urine in high dose methotrexate therapy in patients with advanced cancer
116. (Acute Leukemia Group B): New treatment schedule with improved survival in childhood leukemia. Intermittent parenteral vs. daily oral administration of methotrexate for maintenance of induced remission
117. Therapeutic index of methotrexate as related to dose schedule and route of administration in children with acute lymphocytic leukemia
118. Necrotizing encephalopathy following ventricular instillation of methotrexate
119. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections
120. Brain damage after intrathecal methotrexate
121. Methotrexate‐induced pneumonitis
122. Monitoring high dose methotrexate: value of serum creatinine and plasma methotrexate
123. Pharmacokinetics of high‐dose methotrexate (NSC‐740)
124. Clinical pharmacology of high‐dose methotrexate (NSC‐740)
125. Methotexate (MTX) CSF levels during high dose MTX‐leucovorin therapy
126. The effect of amethopterin on the immune response
127. High dose oral methotrexate with citrovorum factor rescue in squamous cell cancer of the lung
128. 10‐methylpteroic acid
129. Incidence of drug related deaths secondary to high‐dose methotrexate and citrovorum factor administration
130. Lack of effect of high dose methotrexate on lung function
131. Effect of route of administration and effusions on methotrexate pharmacokinetics
132. Treatment of acute lymphocytic leukemia by high‐dose intravenous methotrexate
133. Study of contaminants and metabolites during therapy with high doses of methotrexate
134. Methotrexate in blood, urine and cerebrospinal fluid of children receiving high doses by infusion
135. Scabies Norvegica. Treatment with methotrexate
136. Vincristine enhancement of methotrexate uptake in human lymphoblast cells
137. Membrane transport of methotrexate in human lymphoblasts
138. Biochemical and pathophysiological rationale for amethopterin in psoriasis
139. Methotrexate
140. Neurotoxicity of commonly used antineoplastic agents
141. 14C‐formate incorporation into nucleic acids and protein
142. Remissions produced with the use of methotrexate in patients with mycosis fungoides
143. An in vivo method for determining differential effects of chemotherapy on target tissues in animals and man: Correlation with plasma pharmacokinetics
144. Antagonism of liver methotrexate toxicity in the rat by lipotropic agents
145. Applications of pharmacokinetics to cancer chemotherapy
146. Methotrexate in cerebrospinal fluid